Aurealis Therapeutics

About:

Aurealis Therapeutics is a swiss-finnish private biopharmaceutical company

Website: https://aurealistherapeutics.com/

Top Investors: Tesi, Lynx Capital, Zhejiang Huahai Pharmaceutical

Description:

They exist to develop curative solutions that achieve total and faster healing for non-healing wounds and other complex inflammatory diseases with their four-in-one biologic drug, AUP-16. Their goal is to create solid Phase 2 clinical efficacy data in diabetic foot ulcers and non-clinical proof-of-concept data in other inflammatory diseases by end of 2022, and to engage with strategic partners to ensure that this game changing technology benefits millions of patients.

Total Funding Amount:

$19.1M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Kuopio, Eastern Finland, Finland

Founded Date:

2015-01-01

Founders:

Number of Employees:

11-50

Last Funding Date:

2024-11-13

IPO Status:

Private

Industries: